NCT01605513View on ClinicalTrials.gov

Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Hepatitis C Virus
Interventions
DRUG

interferon

PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.

Trial Locations (1)

13021

Phase One Clinical Trial ward, First Hospital, Jilin University, Changchun

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER

NCT01605513 - Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease | Biotech Hunter | Biotech Hunter